ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,210Medicare Part D Prescriptions Filled, Including Refills

Rank: 114 out of 625

$427K Total Retail Price of All Prescriptions

Rank: 236 out of 625

340 Patients Receiving at Least One Drug in Part D
69%Patients 65 Years and Older
93% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in South Carolina
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

7% of this provider’s 340 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 7,220 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $62 among peers.

Prescriptions per Patient

30 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in South Carolina
AMLODIPINE BESYLATE 1,099 770 1 1
METFORMIN HCL 502 340 2 10
ATORVASTATIN CALCIUM 447 310 3 9
LISINOPRIL 409 306 4 5
LOVASTATIN 332 284 5 58
GLIPIZIDE ER 298 261 6 68
FUROSEMIDE 280 222 7 7
QUINAPRIL HCL 279 237 8 136
METOPROLOL TARTRATE 218 160 9 11
HYDROCHLOROTHIAZIDE 210 131 10 12
RANITIDINE HCL 200 135 11 25
OMEPRAZOLE 191 109 12 6
SIMVASTATIN 188 118 13 2
CLONIDINE HCL 176 153 14 50
ATENOLOL 170 111 15 22
PRAVASTATIN SODIUM 163 125 16 8
GABAPENTIN 151 89 17 14
DIOVAN 142 129 18 28
TRAMADOL HCL 140 95 19 16
DOXAZOSIN MESYLATE 133 116 20 88
NOVOLOG MIX 70-30 123 93 21 187
LEVOTHYROXINE SODIUM 120 80 22 3
CLOPIDOGREL 115 77 23 30
TRIAMTERENE-HYDROCHLOROTHIAZID 107 98 24 174
GLIPIZIDE 106 77 25 56
NIFEDIPINE ER 103 82 26 111
LIPITOR 102 71 27 75
INSULIN SYRINGE 99 74 28 77
AMLODIPINE-ATORVASTATIN 87 46 10 29 272
SERTRALINE HCL 85 56 30 26
HYDROCODONE-ACETAMINOPHEN 85 61 S3 30 4
POTASSIUM CHLORIDE 83 63 32 19
KLOR-CON 10 81 63 33 134
BENICAR 76 52 34 143
PLAVIX 76 61 34 43
LANTUS 73 45 36 54
WARFARIN SODIUM 70 52 37 20
KLOR-CON M20 67 60 38 47
DONEPEZIL HCL 66 66 39 33
NAPROXEN 66 36 39 104
PHENYTOIN SODIUM EXTENDED 65 22 41 119
NOVOLIN 70-30 60 42 42 154
LISINOPRIL-HYDROCHLOROTHIAZIDE 59 34 43 27
PROAIR HFA 57 27 44 57
VENTOLIN HFA 57 13 44 93
SURE COMFORT 57 44 44 347
ADVAIR DISKUS 55 39 47 63
NABUMETONE 54 14 48 179
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.